Jing Song Ph.D. of Beigene was Recently Selected to Receive a Grant under “Returnee Scientific Innovation Initiative Program of Beijing”
In April 2013, Jing Song Ph.D., of Beigene, research program titled, “ Monoclonal antibody drug research targeting cancer stem cells”was selected to receive a Grant under “Returnee Scientific Innovation Initiative Program of Beijing”.
For more information, please contact: email@example.com.
BeiGene is a Chinese life sciences biotechnology company based in the Zhongguancun Life Science Park in Beijing that is focused on discovering and developing innovative oncology drugs that encompass novel small molecules and biologics. BeiGene is pursuing this through its own internal discovery laboratories in China and by in-licensing from pharmaceutical partners investigational therapeutics that address unmet medical needs for Chinese and Asian patients with cancer. BeiGene is also creating a robust biomarkers and bioinformatics platform to enable the identification of specific subsets of patient populations who will most likely benefit from the use of specific drugs or treatments.
For more information, please visit www.beigene.com.